Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
central nervous system
Biotech
Exxel plans $13M IPO to score where other FAAH inhibitors failed
Exxel Pharma is eyeing a listing on the NYSE American to fund human trials for a drug class that has previously struggled to deliver in the clinic.
James Waldron
Feb 3, 2026 11:33am
Rethinking heart attacks as the nervous system gone haywire
Jan 27, 2026 11:00am
MapLight brightens SandboxAQ with CNS deal
Dec 16, 2025 7:30am
Lilly pulls out of CNS portion of $960M collab with Rigel
Nov 5, 2025 7:00am
MapLight goes public via $250M IPO to fund Cobenfy competitor
Oct 27, 2025 6:45am
MapLight illuminates $262M IPO plans to fund Cobenfy competitor
Oct 7, 2025 6:30am
